Drug Trial Radar · NCT04703842
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Last checked: Nov 19, 2026Latest source record: Mar 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
57
Planned (sponsor's estimate)
Start
Sep 23, 2021
Primary completion
Dec 31, 2025
Study completion Dec 2028
Sponsor
- Lead sponsor
- Sardocor Corp.Industry
- Sponsor type
- Industry
- First posted
- Jan 11, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
It is believed that targeted SERCA2a enzyme replacement in HFrEF patients will correct defective intracellular Ca2+ hemostasis, resulting in improved cardiac contractile function and energetics which will, in turn, translate to improved clinical outcomes. Additionally, it is hypothesized that correcting SERCA2a dysfunction will also improve coronary blood flow through correction of the impaired endothelium-dependent nitric oxide-mediated vasodilatation observed in heart failure.
Conditions
- Congestive Heart Failure
- Heart Failure, Systolic
- Heart Failure
- HFrEF - Heart Failure With Reduced Ejection Fraction
Interventions
SRD-001Biological
AAV1/SERCA2a
PlaceboDrug
SRD-001 matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in symptomatic parametersTime frame: Baseline to Month 6 and Month 12
- Change from baseline in symptomatic parametersTime frame: Baseline to Month 6 and Month 12
- Change from baseline in physical parameterTime frame: Baseline to Month 6 and Month 12
- Change from baseline in LV function/remodelingTime frame: Baseline to Month 6 and Month 12
- Rate of recurrent eventsTime frame: Baseline to Month 6 and Month 12
- Rate of adverse eventsTime frame: 6 and 12 months
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
San Diego Cardiac Center
San Diego, California · Recruiting
University of California, San Francisco
San Francisco, California · Recruiting
Washington University in Saint Louis
St Louis, Missouri · Recruiting
University of Texas Southwestern Medical Center
Dallas, Texas · Recruiting
University of Washington Medicine
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.